While gene therapy holds immense promise for treating blue cone monochromacy (BCM), recent research underscores the challenges associated with treating the disease in its later stages. A comparative analysis of adeno-associated virus (AAV) gene therapy in two distinct BCM mouse models has shed light on the molecular mechanisms that limit therapeutic efficacy as the retina ages.
The study evaluated the Opn1mw−/−/Opn1sw−/− (double knockout) and Opn1mwC198R/Opn1sw−/− (missense mutation) mouse models. Researchers found that while AAV-mediated gene supplementation successfully restored cone function and structure in younger mice (under 3 months of age), the efficacy significantly decreased when treatment was administered to mice aged 5 months or older.
Structural analysis revealed rapid degenerative changes in the cone outer and inner segments of older mice. Furthermore, the study observed age-related reductions in transgene expression. This decline may be attributed to decreased cone transducibility, transgene silencing, or disease-related alterations in genome expression.
To address these limitations, the researchers investigated alternative regulatory elements. They discovered that specific cone promoters, such as Pde6c and Cngb3, maintained robust activity even in degenerating cones. Utilizing these optimized promoters in future AAV vectors could enhance transgene expression, thereby extending the therapeutic window and improving treatment longevity for older BCM patients experiencing progressive cone degeneration.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.